John Horton

21.7k total citations · 4 hit papers
104 papers, 16.7k citations indexed

About

John Horton is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, John Horton has authored 104 papers receiving a total of 16.7k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 29 papers in Pulmonary and Respiratory Medicine and 15 papers in Surgery. Recurrent topics in John Horton's work include Cancer Treatment and Pharmacology (17 papers), Glioma Diagnosis and Treatment (10 papers) and Brain Metastases and Treatment (7 papers). John Horton is often cited by papers focused on Cancer Treatment and Pharmacology (17 papers), Glioma Diagnosis and Treatment (10 papers) and Brain Metastases and Treatment (7 papers). John Horton collaborates with scholars based in United States, Canada and France. John Horton's co-authors include Douglass C. Tormey, Martin M. Oken, Paul P. Carbone, Thomas E. Davis, Richard H. Creech, Eleanor McFadden, J. Stuart Nelson, Alan S. Weinstein, Gary H. Lyman and Lodovico Balducci and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

John Horton

101 papers receiving 16.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1982 8.9k citations Douglass C. Tormey, John Horton et al. American Journal of Clinical Oncology profile →
Prognostic effect of weight loss prior tochemotherapy in cancer patients

1980 1.8k citations John Horton, Charles Rosenbaum et al. profile →
Recursive Partitioning Analysis of Prognostic Factors in Three Radiation Therapy Oncology Group Malignant Glioma Trials

1993 1.0k citations W.J. Curran, Charles Scott et al. JNCI Journal of the National Cancer Institute profile →
Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint radiation therapy oncology group and eastern cooperative oncology group study

1983 475 citations John Horton, Alan S. Weinstein et al. Cancer profile →

Peers

Countries citing papers authored by John Horton

Since Specialization

Citations

This map shows the geographic impact of John Horton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Horton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Horton more than expected).

Fields of papers citing papers by John Horton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Horton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Horton. The network helps show where John Horton may publish in the future.

Co-authorship network of co-authors of John Horton

This figure shows the co-authorship network connecting the top 25 collaborators of John Horton. A scholar is included among the top collaborators of John Horton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Horton. John Horton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	P3.02b-042 Reduction in Peripheral Blood Cytokine Levels Observed in EGFR Mutant (EGFRm) Patients Treated with Erlotinib 2017 ·Journal of Thoracic Oncology ·Aaron Lisberg, John Horton, Jonathan W. Goldman, Brian R. Wolf, D. Andrew Tucker, James Carroll, (unknown), (unknown), Maria Velez, (unknown), (unknown), Krikor Bornazyan, (unknown), Xinkai Zhou, Tristan Grogan, David Elashoff, (unknown), Richard J. Pietras, Steven M. Dubinett	1
2	Characteristics of Oncology Clinical Trials 2013 ·JAMA Internal Medicine ·Bradford R. Hirsch, Robert M. Califf, Steven K. Cheng, Asba Tasneem, John Horton, Karen Chiswell, Kevin A. Schulman, David M. Dilts, Amy P. Abernethy	129
3	Mechanisms of Functional Mitral Regurgitation in Ischemic Cardiomyopathy Determined by Transesophageal Echocardiography (from the Surgical Treatment for Ischemic Heart Failure Trial) 2013 ·The American Journal of Cardiology ·Krzysztof S. Gołba, Krzysztof Mokrzycki, Jarosław Dróżdż, Alexander Cherniavsky, Krzysztof Wróbel, (unknown), Haissam Haddad, Gerald Maurer, Michael Yii, Federico M. Asch, Mark D. Handschumacher, Thomas A. Holly, Roman Przybylski, Irving L. Kron, Hartzell V. Schaff, (unknown), John Horton, Kerry L. Lee, Eric J. Velazquez, Paul Grayburn	24
4	Is cytoplasmic localization of topoisomerase I (topo I) a mechanism of resistance for topo I inhibitors? Results from an NCCN sponsored phase II trial of gemcitabine and irinotecan in metastatic breast cancer. 2006 ·Cancer Research ·Stacy Moulder, Nikola Valkov, Jana Gump, Pamela N. Münster, Susan Minton, John Horton, M. Lacevic, (unknown), Dan M. Sullivan	1
5	Suppurative rhinitis associated with Haemophilus species infection in a cat : clinical communication 2004 ·Journal of the South African Veterinary Association ·Rowan J. Milner, John Horton, P.C. Crawford, (unknown), Ann Nguyen	5
6	Fatigue in Women Receiving Adjuvant Chemotherapy for Breast Cancer 1999 ·Journal of Pain and Symptom Management ·Paul B. Jacobsen, Danette Hann, Lora M. Azzarello, John Horton, Lodovico Balducci, Gary H. Lyman	298
7	Oral Combination Chemotherapy in the Management of AIDS-Related Lymphoproliferative Malignancies 1999 ·Drugs ·Scot C. Remick, Nell Sedransk, Richard F. Haase, (unknown), (unknown), Afshin Dowlati, Tipu Nazeer, (unknown), Christina G. Blanchard, (unknown), (unknown), John Horton, John C. Ruckdeschel	7
8	Albendazole for Treatment and Prophylaxis of Microsporidiosis Due toEncephalitozoon intestinalisin Patients with AIDS: A Randomized Double‐Blind Controlled Trial 1998 ·The Journal of Infectious Diseases ·Jean‐Michel Molina, Claude Chastang, Jérôme Goguel, Jean‐François Michiels, Claudine Sarfati, Isabelle Desportes, John Horton, Francis Derouin, J Modaï	56
9	Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. 1998 ·Journal of Clinical Oncology ·Jacob Broeckel, Paul B. Jacobsen, John Horton, Lodovico Balducci, Gary H. Lyman	384
10	Metastatic Adenoid Cystic Carcinoma of Salivary Glands: Case Reports and Review of the Literature 1996 ·Cancer Control ·(unknown), DL Esseltine, (unknown), (unknown), John Horton	20
11	Concurrent 72-Hour Continuous Infusion of Etoposide and Cisplatin in Metastatic Breast Cancer 1996 ·American Journal of Clinical Oncology ·Scot C. Remick, (unknown), (unknown), Jonathan Sporn, (unknown), (unknown), Ronald C. DeConti, John Horton, John C. Ruckdeschel, Gregory Harper	11
12	Recursive Partitioning Analysis of Prognostic Factors in Three Radiation Therapy Oncology Group Malignant Glioma Trials breakdown → 1993 ·JNCI Journal of the National Cancer Institute ·W.J. Curran, Charles Scott, John Horton, J. Stuart Nelson, Alan S. Weinstein, Andreas Fischbach, Chia‐Hsien Chang, Marvin Rotman, S. Asbell, Robert E. Krisch, Diana F. Nelson	1026
13	Recurrent Pneumococcal Pneumonia in an HIV-Positive Patient With Lymphoid Interstitial Pneumonitis 1992 ·Southern Medical Journal ·(unknown), John Horton, (unknown)	2
14	Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials 1992 ·Journal of Neuro-Oncology ·Walter J. Curran, Charles Scott, John Horton, (unknown), Alan S. Weinstein, (unknown), Andreas Fischbach, (unknown), Marvin Rotman, (unknown), William D. Powlis	85
15	Tamoxifen in advanced prostate cancer: An ECOG pilot study 1988 ·The Prostate ·John Horton, Charles Rosenbaum, Frank J. Cummings	16
16	Combination hormone therapy for metastatic breast cancer: An ECOG study of megestrol and aminoglutethimide 1987 ·Cancer ·John Horton, Matthew Knuiman, Alan Keller, (unknown), (unknown), Richard G. Hahn, Richard J. Rosenbluth, Douglass C. Tormey	7
17	Follow-up of breast cancer patients 1984 ·Cancer ·John Horton	42
18	Comparison of 5-FU and doxorubicin in the treatment of carcinoma of the bladder. 1983 ·PubMed ·(unknown), (unknown), Robert G. Hahn, John Horton	10
19	Attitudes towards cancer. II: A comparative analysis of cancer patients, medical students, medical residents, physicians and cancer educators 1982 ·Cancer ·(unknown), John C. Ruckdeschel, Christina G. Blanchard, Michael J. Rohrbaugh, John Horton	25
20	Small Cell Anaplastic Carcinoma of the Lung: Changing Concepts and Emerging Problems 1979 ·CA A Cancer Journal for Clinicians ·John C. Ruckdeschel, (unknown), (unknown), (unknown), John Horton	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact